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Background: The hemodialysis (HD) population has a particularly high incidence of amputation, which is likely
associated with decreased tissue oxygenation during HD. However, information about the risk factors leading to
amputation in peritoneal dialysis (PD) patients is limited. Here, we have investigated the association between the
use of hypertonic peritoneal dialysate (HPD) and subsequent amputation in PD patients.
Methods: Based on the data from the Taiwan National Health Insurance research database, this observational
cohort study enrolled 203 PD patients who had received HPD early during treatment and had not undergone
amputation and 296 PD controls who had not undergone amputation. Subjects were followed through until the
end of 2009 and the event rates of new non-traumatic amputation were compared between groups.
Results: The incidence of amputation was 3 times higher for the HPD cohort than for the comparison cohort
(23.68 vs. 8.01 per 1000 person-years). The hazard ratio (HR) for this group, estimated using a multivariable Cox
model, was 2.48 (95% confidence interval [CI] = 1.06–5.79). The HR for patients with both diabetes and early
adoption of HPD increased to 44.34 (95% CI = 5.51-357.03), compared to non-HPD non-diabetic PD controls.
Conclusion: Early utilization of HPD in PD patients is associated with increasing risk of amputation; this risk
considerably increases for those with concomitant diabetes.
Keywords: Non-traumatic amputation, Hypertonic dialysate, Peritoneal dialysisBackground
Non-traumatic extremity amputation, usually related to
diabetes, places a considerable burden on individuals,
families, and health care finances [1]. Renal failure and
dialysis initiation are recognized risk factors for non-
traumatic amputation [2,3]. Compared with the general
population, dialysis patients experience higher amputation
incidence and have much higher post-amputation mortality
rates [4]. O’Hare et al reported that hemodialysis (HD) pa-
tients who were male, diabetic, had been previously* Correspondence: cch@mail.cmuh.org.tw; fcsung@mail.cmu.edu.tw
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reproduction in any medium, provided the ordiagnosed with peripheral vascular disease (PVD), had high
mean systolic blood pressure, or elevated phosphate levels
had increased risks of future amputation [5]. Only a few
studies have investigated the risk factors of amputation in
peritoneal dialysis (PD) patients, and these have had limited
sample size [6,7]. Pliakogiannis et al studied 71 diabetic pa-
tients receiving PD and noted that low levels of albumin,
peripheral neuropathy, and coronary artery disease were as-
sociated with foot lesions [7]. In the clinic, we noted that
PD patients who required hypertonic peritoneal dialysis
(HPD) solution soon after the initiation of PD were more
likely to require amputation. We hypothesize that early
HPD use is related to future amputation in PD patients. To
test this hypothesis, we conducted a retrospective cohort
analysis to assess the incidence of amputation among PD. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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utilization within the first 6 months of initiating PD.
Methods
Data sources
The present study was based on data obtained from the
National Health Insurance Research Database (NHIRD)
of the National Health Research Institute. The universal
National Health Insurance program, launched in March
1995, provides affordable health care to nearly 99% of
the population and is contracted with 97% of clinics and
hospitals throughout the nation. From the NHIRD, we
extracted a Longitudinal Health Insurance Database
(LHID), which contained one million beneficiaries, ran-
domly selected from 1996-2000 insurers. The LHID
database contains comprehensive annual health care
data for all beneficiaries including birth date, gender,
diagnostic codes, prescriptions, procedures, and surger-
ies. The disease diagnosis was coded with International
Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) form outpatient, inpatient and
catastrophic illness file. Personal information was de-
identified before the release of the research database,
thus this study was exempt from approval by the Institu-
tional Review Board.
Study population
Based on inpatient and outpatient claims, we identified
patients who had been first diagnosed with end-stage
renal disease (ESRD; ICD-9-CM code 585) and were
receiving PD during 1998–2009. Among these new PD
patients, subjects prescribed HPD (i.e., 7.5% icodextrin
solution or 4.25% dextrose solution) within the first 6
months of initiating PD were identified as the HPD co-
hort. Those new PD patients who did not received HPD
within the first 6 months of initiating PD were consid-
ered as the comparison cohort. The index date was the
date of initiating PD in the control and in the study co-
hort. The following patients were excluded: (1) patients
who underwent amputation before the index date, (2)
patients who experienced severe illness but did not have
a record of PD, and (3) patients who had received HD or
had undergone renal transplantation before the index
date. We followed the cohorts until diagnosis and sur-
gery for the first amputation, either major or minor,
(ICD-9-CM 785.4 and 440.24; ICD-9-CM 84.10-84.17)
been made, withdrawal from insurance, loss to follow-up,
or December 31, 2009, whichever was the latest.
Baseline comorbidities thought to be associated with
subsequent amputation were also analyzed. These in-
cluded diabetes (ICD-9 code 250), hypertension (ICD-9
codes 401-405), ischemic heart disease (ICD-9 codes
410-414, A270, and A279), previous foot ulcers (ICD-9
codes 707.1-707.9), diabetic neuropathy (ICD-9 codes353.5, 357.2, 354.0-355.9, and 337.1), peripheral vascular
disease (PVD, ICD-9-CM codes 443.89 443.9), hyper-
parathyroidism (ICD-9-CM codes 252.0), heart failure
(ICD-9-CM codes 428), diabetes duration, and dialysis
vintage.
Statistical analysis
The differences in demographic characteristics and
comorbidities between the study and comparison cohort
were examined by using Chi-square test for categorical
variables and t-test for continuous variables. We used
the Kaplan-Meier method to estimate the amputation-
free rates and the log-rank test to examine the statistical
significance of the differences between the study groups.
Cox proportion hazard model was used to estimate the
hazard ratios (HRs) and 95% confidence intervals (CIs)
for the risk of subsequent amputation. We further ana-
lyzed the interaction between early use of hypertonic di-
alysate and diabetes. We performed all statistical analysis
using SAS 9.1 statistical software (SAS Institute, Inc.,
Cary, NC, USA) and drew the cumulative incidence
curve using R software (R Foundation for Statistical
Computing, Vienna, Austria). The differences were con-
sidered significant if a two-sided P value was less than or
equal to 0.05.
Results
We identified 499 PD patients eligible for the study, with
203 patients in the HPD cohort and 296 patients in the
comparison cohort. The sociodemographic characteris-
tics and comorbidity histories of the 2 groups are shown
in Table 1. Compared with the comparison cohort, the
HPD cohort was older (mean ages 56.1 vs. 50.9 years,
p = 0.0007), and has more prevalence of hypertension
(89.7% vs. 83.4%, p = 0.0498), diabetes (43.8% vs. 26.7%,
p < 0.0001), diabetes neuropathy (9.4% vs. 4.4%, p =
0.0261) and heart failure (29.6% vs. 20.6%, p = 0.0220).
The 2 cohorts did not significantly differ with respect to
gender, peripheral vascular disease, and hyperparathyr-
oidism. The mean follow-up duration for the HPD
cohort was 3.1 years, which is approximately 1.1 years
shorter than that for the comparison cohort.
During the 12-year study period, we identified 25 new
amputation patients (15 in the HPD cohort and 10 in
the comparison cohort). The incidence density of ampu-
tation was higher for the HPD cohort (23.68 per 1000
person-years) than for the comparison cohort (8.01 per
1000 person-years). Thus, the incidence of amputation
in the HPD cohort was approximately 3 times higher
than that of the comparison cohort. Multivariate regres-
sion analysis showed that the risk for new amputation in
the HPD cohort was higher than that for the comparison
group (HR = 2.48; 95% CI = 1.05–5.79) after adjusting
for demographic status, hypertension, ischemic heart





Comparison cohort HPD cohort
N = 296 (%) N = 203 (%)
Age, mean (SD) years 50.9 (17.1) 56.1 (15.8) 0.0007
≦30 41 (13.9) 12 (5.9) 0.0030
31-50 107 (36.1) 59 (29.1)
51-70 105 (35.5) 96 (47.3)
>70 43 (14.5) 36 (17.7)
Sex 0.3500
Female 170 (57.4) 108 (53.2)
Male 126 (42.6) 95 (46.8)
Comorbidity
Hypertension 247 (83.4) 182 (89.7) 0.0498
Ischemic heart disease 81 (27.4) 70 (34.5) 0.0891
Diabetes 79 (26.7) 89 (43.8) <0.0001
DM foot ulcer 5 (1.7) 5 (2.5) 0.5445
DM neuropathy 13 (4.4) 19 (9.4) 0.0261
Heart failure 61 (20.6) 60 (29.6) 0.0220
Peripheral vascular disease 5 (1.7) 5 (2.5) 0.5445
Hyperparathyroidism 7 (2.4) 8 (3.9) 0.3111
Follow-up duration, mean (SD) 4.2 (2.9) 3.1 (2.8) <0.0001
DM duration, mean (SD) 9.8 (3.3) 9.7 (3.6) 0.8736
*t-test.
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that among patients younger than 70, the rate of
amputation for both cohorts increased with age (Table 2).
The cumulative incidence of amputation, estimated
using the Kaplan-Meier methods showed significant
differences and was 0.11-times higher for the HPD co-
hort than for the comparison cohort (Figure 1, log-rank
test p = 0.001). We further analyzed the interaction be-
tween diabetes mellitus (DM) and early utilization of
HPD (Table 3) and found that diabetic patients had a
higher incidence of amputation among all categories,Table 2 Incidence of amputation and multivariate Cox propo
for PD patients using hypertonic solution
Comparison cohort HPD co
Variable Event PY Rate Event PY
Overall 10 1248 8.01 15 63
Age group
<50 1 774 1.29 4 31
51-70 8 374 21.35 8 27
>70 1 99 10.08 3 47
*Incidence rate, per 1000 person-years.
HR hazard ratio, CI confidence interval.
Model adjusted for age, sex, hypertension, ischemic heart disease, heart failure andwith or without the use of HPD (67.07 and 40.61 per 1000
person-years, respectively). Non-diabetic HPD patients
also had a higher incidence of amputation than
non-diabetic non-HPD patients (4.55 vs. 0.97 per 1000
person-years), but the risk was not significant (HR = 3.48,
95% CI = 0.31–38.67). For patients who had DM and were
receiving HPD, the incidence of amputation increased fur-
ther to 78.51 per 1000 person-years, with an adjusted HR
of 44.34 (95% CI = 5.51–357.03). However, the sample size
was not large enough to have the power to detect a signifi-
cant interaction (p for interaction > 0.05).rtional hazards regression analysis measured hazard ratio
hort
Rate Crude HR (95% CI) Hazard ratio (95% CI)
3 23.68 2.98(1.33-6.66) 2.48(1.06-5.79)
1 12.86 10.32(1.15-92.58) 1.20(0.11-12.59)
5 29.60 1.41(0.52-3.78) 3.06(0.92-10.22)
63.43 6.24(0.63-61.52) 5.65(0.51-62.54)
diabetes.
Figure 1 Cumulative incidence of amputation in hypertonic
dialysate cohort and comparison cohort.
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In this nationwide retrospective cohort study, we have
illustrated the relationship between early utilization of
HPD and subsequent amputation in PD patients. The
use of HPD within the first 6 months after initiation of
PD was associated with a 2.48-fold increase in the HR of
new amputation compared to that for the comparison
cohort. Furthermore, HPD cohort who had concomitant
DM carried the highest risk, with 44.34 times the inci-
dence of amputation seen in non-HPD non-diabetic
patients.
Recent commencement of dialysis therapy has been
recognized as an influential risk factor for lower limb
amputation in the DM population [2]. Several re-
searchers have studied the pathophysiological changes
that occur during hemodialysis, which may contribute to
these limb-threatening conditions [8-12]. Systemic hyp-
oxemia, microcirculatory hypoperfusion, and decreased
transcutaneous oxygen tension of the lower limbs can
occur during and after HD; all these factors could lead
to limb ischemia and amputation [9-11]. Although there
are no comparable data on PD, it is possible that HPD
could produce similar effects. For instance, HPD mightTable 3 The interaction between diabetes and hypertonic
solution for amputation risk
HPD Diabetes Rate Crude HR (95%CI) Adjusted HR (95%CI)
No No 0.97 ref ref
No Yes 40.61 44.32(5.53-355.21) 19.33(2.30-162.12)
Yes No 4.55 4.80(0.43-53.02) 3.48(0.31-38.67)
Yes Yes 67.07 78.51(10.3-614.29) 44.34(5.51-357.03)
*Incidence rate, per 1000 person-years.
HR hazard ratio, CI confidence interval.
Model adjusted for age, sex, hypertension, heart failure and ischemic
heart disease.
p value for interaction > 0.05.create a more rapid fluid shift into the peritoneal cavity,
reducing microcirculatory blood flow and tissue oxygen
tension. Furthermore, elevated blood pH levels could
cause a shift in the oxygen dissociation curve, leading to
tissue hypoxia [12]. Furthermore, the use of human re-
combinant erythropoietin and possible vasoconstriction
of microcirculation during ultrafiltration might cause
rheological changes and impair microvascular perfusion
[6,13]. Moreover, PD patients placed on HPD have clin-
ical signs of fluid overload, such as hypertension and tis-
sue edema, which may worsen tissue oxygenation status.
Li et al. found that PD patients have higher incidence
rates of mesenteric ischemia than HD patients, indicat-
ing that PD therapy might contribute to the advance-
ment of microvascular disease [14]. They hypothesized
that chronic exposure to high glucose levels caused
micro- and macrovascular damage and contributed to
advancing atherosclerosis, which could lead to organ
ischemia.
In our study, diabetes was associated with an RR of
19.33 for amputation in PD patients. This result is in ac-
cordance with those of previous studies that found that
diabetes was the strongest risk factor for amputation in
HD patients [5,15-17]. Furthermore, our results showed
that diabetic patients tended to initiate HPD earlier than
those without diabetes. The risk of amputation with
early utilization of HPD and concomitant diabetes was
44.34 times greater than that for PD patients who were
neither diabetic nor given HPD therapy. Since diabetics
are at greater risk for early ultrafiltration failure,
microvasculopathy, and autonomic neuropathy [18-20],
early utilization of high-strength dialysate might lead to
longer glucose exposure, increased glucose toxicity to
the vessels, and finally, limb ischemia, than in non-
diabetics. Therefore, we hypothesize that early HPD
utilization in diabetic PD patients promotes atherogen-
esis and/or microvascular hypoperfusion.
Among patients younger than 70, the rate of amputa-
tion for both cohorts increased with age. This is likely
due to an increased risk of death with surgery for this
population, leading to a lower probability of amputation
for patients over 70. Eagger et al. found a positive associ-
ation between increasing age and amputation in the
ESRD population [4]. Combes et al. observed that while
older age was associated with a decreased probability
of amputation in diabetic HD patients, it actually in-
creased the likelihood of amputation among non-
diabetics [15]. Pilakogiannis et al reported that age is
not related to developing PVD, but no further informa-
tion is available about the association between age and
amputation in PD patients [7]. The inconsistency of
these results across studies likely reflects the diverse
medical care and mortality rates of different renal
populations.
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tion and care to HD and PD patients significantly im-
proves foot care and reduces the need for amputation
[21]. For instance, introduction of the Staged Diabetes
Management clinical pathways for dialysis patients have
shown to lower the amputation rate considerably [22].
Chiropody been reported could prevent amputation in
diabetic PD patients [23]. Thus, amputation in dialysis
patients might be preventable in many cases when com-
prehensive care is provided.
Our study has several strengths. First, it utilized the
NHIRD database. This large population database with
comprehensive electronic medical records provided
complete data about the incidence of amputation as well
as important information including that pertaining to
age, sex, types of dialysis solution, dialysis vintage, and
comorbidities. Second, we excluded subjects with previ-
ous amputations and included only PD patients who
received long-term follow up care. Excluding patients
with past amputation might eliminate possible bias with
regard to analyzing future amputation and provide a
clearer interpretation of the effect of HPD on limb
ischemia.
The several limitations of our study should also be
mentioned. First, the number of subjects included was
relatively small, leading to large confidence intervals.
Furthermore, it is possible that some patients had sub-
clinical PVD. However, we also considered comorbidities
such as foot ulcers, heart failure, and cardiovascular risk
factors associated with PVD, suggesting that any effect
of undiagnosed PVD on our results was likely to be sub-
tle. We also did not have precise information about
smoking status and the calcium and phosphate levels,
which might be associated with the risk of future ampu-
tation. However, Pliakogiannis et al reported that time
average Kt/v, creatinine clearance, serum calcium levels,
calcium and phosphate production, and intact parathy-
roid hormone level are not associated with amputation
in PD patients [7]. We also lacked information about the
subjects’ scores on baseline measures of circulatory sta-
tus, such as the ankle-brachial index (ABI) [24]. Given
that ABI is not correlated with the severity of peripheral
arterial disease among dialysis patients and would be
falsely elevated by arterial calcification, it may be appro-
priate to overlook ABI in the current study.
In conclusion, along with diabetes, early utilization
of HPD is associated with the subsequent risk of ampu-
tation in PD patients. We suggest that PD patients be
provided intensive education on foot protection and
screening for evidence of limb ischemia, especially
those who received HPD early. Further studies are
required to determine the efficacy and cost effective-
ness of integrated and multidisciplinary foot care in
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